Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Photocure Partner Asieris confirms Hexvix Phase III clinical trial in China meets endpoint

Press Release – Oslo, Norway, August 11, 2023: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) has communicated today that the Hexvix[®] Phase III bridging trial in China has successfully met its primary research endpoint.The objective of this multicenter Phase III trial is to support regulatory approval of Hexvix in Mainland China. The bridging trial is intended to confirm results from prior clinical trials regarding the safety and detection benefits of blue light cystoscopy (BLC®) with Hexvix compared to white light

NoHo Partners Plc: Managers' transactions (Niemi)

NoHo Partners PlcMANAGERS' TRANSACTIONS 11.8.2023 12:00NoHo Partners Plc: Managers' transactions (Niemi) ____________________________________________ Person subject to the notification requirementName: Hanna-Stiina NiemiPosition: Closely associated person (1):Person Discharging Managerial Responsibilities In IssuerName: Mika NiemiPosition: Member of the Board Issuer: NoHo Partners OyjLEI: 743700DYZ6R1QNLWQA56Notification type: INITIAL NOTIFICATIONReference number: 36477/4/8____________________________________________ Transaction date: 2023-08-09Venue:

Major shareholder announcement

Company announcement 20/2023 With reference to section 30 of the Capital Markets Act, HusCompagniet A/S (the “Company”) hereby announces that Lind Value II ApS, owned by Henrik Lind through Lind Invest ApS, has notified the Company that Lind Value II ApS, holds 3,337,792 shares and 16,688,960 voting rights, corresponding to 15.37% of the total voting rights and the total share capital in the Company. For additional information, please contact: HusCompagniet Jesper Høybye, Group CFO                           +45 30 58 46 42About HusCompagniet HusCompagniet is a leading

Promising signals of effect in Annexin's RVO-study

Annexin Pharmaceuticals AB today announces that an independent evaluation of potential signals of effect has been carried out in the company's Phase 2-study in retinal vein occlusion with the investigational new drug ANXV. Positive findings justify an extended follow-up period.A group of leading independent US ophthalmologists has conducted an evaluation of the available information from patients treated so far in the placebo-controlled study. The evaluation confirmed an unexpectedly long duration of effect with a single dose of standard of care anti-VEGF treatment in two of five treated

Techstep ASA: Invitation to presentation of Q2 2023 financial results

Techstep ASA will release its second quarter 2023 financial results on Friday 18 August 2023 at 07:00 CET. The quarterly report and presentation will be made available on the company's website: www.techstep.io/investor, as well as on www.newsweb.no.   The Q2 presentation will be given in English by CEO, Børge Astrup and CFO, Ellen Solum.  A Q&A session will take place as a virtual event on 18 August at 08:00 CET. Please join the Teams-session by clicking here 

Contract awards in Brazil

Solstad Offshore ASA (Solstad) has been awarded two contracts from Brazilian Clients that further strengthen Solstad’s position as one of the main operators of high-end offshore vessels in Brazil. CSV Normand Pioneer has been awarded an extension of its charter contract with the Brazilian oil company PRIO for a period of 18 months to August 2025. The vessel will support PRIO’s E&P activities in Brazilian waters. Solstad and Equinor Brazil have entered into an agreement to convert the PSV Normand Carioca to a Well Stimulation Vessel (WSV) and extend the present contract until December

Notification of managers’ and closely related parties’ transactions with Dampskibsselskabet NORDEN A/S’ shares in connection with share buy-back program

ANNOUNCEMENT NO. 113 - 11 AUGUST 2023   In connection with the announced share buy-back program in NORDEN, A/S Motortramp continuously sells shares pro rata and the market is to be informed accordingly – see the attached file and announcement no. 112/23. A/S Motortramp participates in NORDEN’s share buy-back program by selling shares pro rata in order to maintain the current ownership of just under 32% of the shares in NORDEN.     Kind regards, Dampskibsselskabet NORDEN A/S   Martin Badsted CFO       For further information: Stig Frederiksen, Head

#teamZalaris finishes Zalaris Norseman Xtreme Triathlon – known as the toughest triathlon in the world

For the fourth year in a row, Zalaris proudly sponsors the Zalaris Norseman Xtreme Triathlon. This unique event aims to ‘inspire and demonstrate the robustness of what ordinary people can achieve’.#teamZalaris for Norseman 2023 comprises of Torsten Neufeld, Anders Spilling, Sophie Buer, Stanisław Kłęk, Simone Kragh Jacobsen, Ross Creber and Andreas Martinussen. The team has raised over 550,000 NOK benefitting  AKTIV Against Cancer , The 5k Your Way  Initiative, provided by MOVE Charity , Hopp Children's Cancer

The subscription price for warrants series TO2 in Biosergen has been determined to SEK 0.66 and the exercise period starts on August 14, 2023

Stockholm, Sweden - August 11, 2023 - Biosergen AB ("Biosergen" or the “Company") completed a rights issue of units on Nasdaq First North Growth Market in October 2022 (the “Rights Issue”). The exercise period for warrants series TO2 issued in conjunction with the Rights Issue begins on Monday, August 14, 2023. Each warrant series TO2 entitles to subscription of one (1) new share in the Company at an exercise price of SEK 0.66.Summarized terms for warrants series TO2:Exercise period: August 14 – August 25, 2023.Issue size: 8,595,531 warrants series TO2, which entitle to subscription of

PEPTONIC Medical AB (publ) org nr 556776–3064 HALF YEAR REPORT Period january – june 2023

GROUP 2023 SECOND QUARTER (April-June) · Net sales of products SEK 11 930 (12 354) thousand · Gross profit SEK 6 214 (6 269) thousand, 52% (51%) · Operating loss SEK -7 377 (-8 146) thousand · Loss per share -0,01 (-0,04) SEK   2023 FIRST HALF YEAR (April-June) · Net sales of products SEK 20 804 (21 262) thousand · Gross profit SEK 11 084 (11 865) thousand, 53% (56%) · Operating loss SEK -14 031 (-19 021) thousand · Loss per share -0,01 (-0,08) SEKMessage from our CEO Important steps towards establishing a leading Swedish Femtech Company We are

NYAB Plc and Andament II Sulautuva Oy have completed the merger

NYAB PlcCOMPANY ANNOUNCEMENT11 August 2023 at 09:45NYAB Plc and Andament II Sulautuva Oy have completed the merger The Board of Directors of NYAB Plc ("NYAB" or the"Company") and Andament II Sulautuva Oy have executed the merger of Andament II SulautuvaOy into NYAB in accordance with the merger plan signed on 24 February 2023 and supplemented on 18 April 2023 (the "Merger Plan"), as measures required by the merger, including the full demerger of Andament Group Oy, have been completed. The execution of the merger has been registered with the Trade Register today, on 11 August 2023.

Wyld Networks AB today announces that the outstanding loan to Formue Nord Fokus A/S has been repaid in full

Wyld Networks AB today announces a successful repayment of a previous loan financing of SEK 4.7 million, interest included, to Formue Nord Fokus A/S.As a consequence of the repayment, Wyld Networks presently holds no outstanding loans.   For further information about Wyld Networks, please contact: Alastair Williamson, CEO Wyld NetworksE-mail: alastair.williamson@wyldnetworks.comTel: +44 7 824 997 689   About Wyld Networks Wyld Networks develop and sells innovative wireless technology solutions that enables affordable connectivity anywhere in the World, addressing the

Publication of United Bankers Plc’s 2023 Half-Year Financial Report and invitation to result presentation on 25 August 2023

United Bankers Plc PRESS RELEASE 11 August 2023 at 09:00 EEST   Publication of United Bankers Plc’s 2023 Half-Year Financial Report and invitation to result presentation on 25 August 2023   United Bankers Plc will publish its Half-Year Financial Report for the period January-June 2023 on Friday 25 August 2023 at approximately 9.00 am. The Half-Year Financial Report will be available on the company’s website at www.unitedbankers.fi  after publishing. Patrick Anderson, CEO, will present the result to analysts and press at the

Swedish publisher Bonnier brings back their titles to Readly

Readly, the European market leader in digital magazines and newspapers, signs an agreement with Bonnier News AB and Bonnier Publications AS which means that Readly's subscribers get access to 35 additional digital titles from Bonnier including daily newspapers Expressen, GT and Kvällsposten, alongside magazines Damernas Värld, Allt om Mat and Teknikens Värld. With the content from Bonnier, Readly offers its subscribers 7500 titles to read on its app. The addition of the titles from Bonnier further strengthens Readly's position and brings new growth opportunities in the Nordic

Remedy Entertainment Plc: Investment phase continues with the Q4 release of Alan Wake 2 in sight

Remedy Entertainment Plc | Stock exchange release, August 11, 2023, at 09:00 a.m. (EEST)   Remedy Entertainment Plc | Half-Year Financial Report January–June 2023     Remedy Entertainment Plc: Investment phase continues with the Q4 release of Alan Wake 2 in sight The response to the Alan Wake 2 marketing campaign has been promising   The Half-Year Financial Report is unaudited. Figures in parentheses refer to the comparison period in the previous year, unless otherwise stated. Highlights from April–June 2023 •          Revenue decreased by 5.3% to EUR 8.9 (9.4)

Kamux Corporation’s Half Year Financial Report for January 1–June 30, 2023: Revenue increased and adjusted operating profit at previous year’s level

Kamux Corporation, Half Year Financial Report, 11.8.2023 at 9:00 Kamux Corporation’s Half Year Financial Report for January 1–June 30, 2023: Revenue increased and adjusted operating profit at previous year’s level This is a summary of Kamux Corporation’s Half Year Financial Report for January 1–June 30, 2023. The complete report is attached to this release and is also available at the company website at kamux.com . The figures in parentheses refer to the comparison period, i.e., the same period in the previous year, unless stated otherwise. April–June

Irisity AB (publ) reports a quarter of synergy, strategic refinement, and growth.

The CEO comments on the second quarter:   Irisity's past quarter has been marked by transformation and growth. Key changes include a rejuvenated executive team and optimized board, focusing on partnership-centric sales and AI/Machine Learning innovation.   Q2 revenue increased to 30.2 MSEK, with a healthy gross margin of 83.9%. New regional partners are paving the way for future expansion. Although investments during the period have temporarily reduced available cash, these are to be seen as integral to long-term value creation. Additionally, a shift towards a partner-first

Navamedic ASA: Significant growth across the business

Oslo, 11 August 2023 – Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality products to hospitals and pharmacies, today announces its results for the second quarter and first half of 2023. Having experienced strong growth across the business, Navamedic grew its revenues for the first half of 2023 by 41.7 per cent, amounting to NOK 245.7 million.For the first half of 2023, the gross margin was 40.9 per cent, down from 42.9 per cent last year. Adjusted EBITDA (EBITDA less acquisition cost) was NOK 26.3 million, up from NOK 23.3 million in the corresponding

Lytix Biopharma’s licensing partner Verrica Pharmaceuticals Inc. reports interim Phase 2 data with LTX-315

· Promising clinical results showed clearance of basal cell carcinoma lesions in 4 of 6 patients. · Potential as non-surgical therapeutic approach for basal cell carcinoma, the most common form of cancer in the USOslo, 11 August 2023. Lytix Biopharma – Lytix Biopharma AS (“Lytix”) (Euronext Growth Oslo: LYTIX), a clinical-stage biotech using host-defense peptide derived molecules to kill cancer cells and kick start the immune system, announces that its licensing partner Verrica Pharmaceuticals Inc (“Verrica”) has reported lesion clearance data from Part 1 of an ongoing Phase 2 study of

Oneflow interim report Q2 2023: All-time high sales despite a tough market

Press release11 August 2023 Oneflow publishes its interim report for the second quarter of 2023: April - June 2023 (compared to the same period last year) · Net sales increased 46% to MSEK 23.9 (16.5). Share of Net sales outside Sweden increased to 30% (24) with paying users in 35 countries. · EBIT was MSEK -25.4 (-13.4), with an EBIT margin of -105.9% (-81.3). · Basic earnings per share amounted to SEK -0.97 (-0.58) and diluted to SEK-0.97 (-0.58). · Total ARR YoY increased 48% to MSEK 110.8 (74.7).  · Net New ARR for the second quarter increased 25% to MSEK 11.3 (

Nilar International AB Interim Report Q2 2023

Nilar is ready to take the next step.April – June 2023 in summary ·Net sales, MSEK 2.1 (1.8). ·Gross profit MSEK -36.6 (-35.0). ·EBITDA[1] MSEK -38.9 (-42.8). ·Operating profit (EBIT) MSEK -58.9 (-58.5). ·Profit for the period MSEK -72.9 (-67.8). ·Earnings per share SEK -0.23 (-1.33). January – June 2023 in summary ·Net sales, MSEK 5.2 (-2.4). ·Gross profit MSEK -66.8 (-75.8). ·EBITDA[1] MSEK -83.8 (-90.9). ·Operating profit (EBIT) MSEK -123.7 (-122.0). ·Profit for the period MSEK -143.8 (-142.1). ·

Nilar presents updated business plan, adopts new targets for the period up to and including 2027 and reviews the company's financing alternatives

INSIDE INFORMATION: Nilar International AB (publ) ("Nilar" or the "Company") today presents an updated business plan with a number of prioritized focus areas for the period up to and including 2027. The business plan includes both the launch of two new versions of Nilar's battery and significant investments in additional production capacity to reach larger volumes and thus increased cost efficiency. In parallel, Nilar intends to implement a number of measures to improve the Company's financial structure and financial position. In addition, the Board of Directors of Nilar has adopted updated

Invitation to Exel Composites’ Q2 2023 financial results briefing on 18 August 2023

EXEL COMPOSITES PLC          INVESTOR NEWS          11 AUGUST 2023 at 9:00 EETExel Composites will publish its Q1-Q2 2023 Half Year Financial Report on Friday 18 August 2023 at approximately 9:00 EET. Investors, analysts and journalists are invited to participate in the financial results briefing at 12:30 EET on the same day. The briefing will be hosted by President and CEO Paul Sohlberg and CFO Mikko Rummukainen.   The briefing will be organized online. To participate in the event, please register in advance by sending an email to investor@exelcomposites.com by Thursday 17 August

There are no items matching the current filter
There are no more items matching the current filter
Back to top